| 2019-FLAH-68419 | |
| Vancomycin-resistant enterococcus (VRE) is a leading cause of hospital-acquired infections in the US. There is an unmet need for new treatments of VRE, as infected patients frequently exhaust treatment options when fighting bacterial resistance. Researchers at Purdue University have developed small molecules to combat drug-resistant enterococcus. These acetazolamide analogs demonstrated a 2 to 4-log reduction in VRE gastrointestinal colonization in mice and were superior to linezolid, the current standard of care, in clearing VRE in internal organs. Additionally, they were shown to selectively target VRE without harming the normal gut microbiota. The application for these compounds is for the treatment of drug-resistant enterococcus. Advantages: -Improved potency against VRE -High selectivity for VRE Potential Applications: -VRE treatment |
|
|
|
|
Dec 18, 2019
PCT-Patent
WO
(None)
(None)
Dec 19, 2018
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |